These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6137850)

  • 21. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements.
    Tan YL; Zhou DF; Zhang XY
    Schizophr Res; 2005 May; 74(2-3):263-70. PubMed ID: 15722005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
    Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
    Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
    Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
    Psychopharmacol Bull; 1992; 28(1):101-7. PubMed ID: 1609034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tardive dyskinesia in outpatients on depot phenothiazine.
    Neehall J
    West Indian Med J; 1989 Dec; 38(4):228-33. PubMed ID: 2576166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, double-blind, placebo-controlled trial.
    Loonen AJ; Verwey HA; Roels PR; van Bavel LP; Doorschot CH
    J Clin Psychopharmacol; 1992 Feb; 12(1):39-42. PubMed ID: 1348061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of tardive dyskinesia with vitamin E.
    Egan MF; Hyde TM; Albers GW; Elkashef A; Alexander RC; Reeve A; Blum A; Saenz RE; Wyatt RJ
    Am J Psychiatry; 1992 Jun; 149(6):773-7. PubMed ID: 1350428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?
    Jeste DV; Wyatt RJ
    J Clin Psychiatry; 1981 Dec; 42(12):455-7. PubMed ID: 6118358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroleptic plasma levels and tardive dyskinesia: a possible link?
    Nasrallah HA
    Schizophr Bull; 1980; 6(1):4-7. PubMed ID: 6102792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changing epidemiology of tardive dyskinesia: an overview.
    Jeste DV; Wyatt RJ
    Am J Psychiatry; 1981 Mar; 138(3):297-309. PubMed ID: 6110344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tardive dyskinesia in neuroleptic medicated mentally handicapped subjects.
    Rao JM; Cowie VA; Mathew B
    Acta Psychiatr Scand; 1987 Nov; 76(5):507-13. PubMed ID: 2893512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of parkinsonism and antiparkinsonian therapy in the subsequent development of tardive dyskinesia.
    Elliott KJ; Lewis S; el-Mallakh RS; Looney SW; Caudill R; Bacani-Oropilla T
    Ann Clin Psychiatry; 1994 Sep; 6(3):197-203. PubMed ID: 7881501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroleptic plasma levels and tardive dyskinesia.
    Giller E
    Schizophr Bull; 1980; 6(3):391-2. PubMed ID: 6105706
    [No Abstract]   [Full Text] [Related]  

  • 34. A survey of tardive dyskinesia in psychiatric inpatients in Japan.
    Koshino Y; Madokoro S; Ito T; Horie T; Mukai M; Isaki K
    Clin Neuropharmacol; 1992 Feb; 15(1):34-43. PubMed ID: 1349507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum neuroleptic concentrations and tardive dyskinesia.
    Jeste DV; Linnoila M; Wagner RL; Wyatt RJ
    Psychopharmacology (Berl); 1982; 76(4):377-80. PubMed ID: 6126895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study.
    Ganzini L; Heintz RT; Hoffman WF; Casey DE
    Arch Gen Psychiatry; 1991 Mar; 48(3):259-63. PubMed ID: 1671743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.
    Glazer WM; Morgenstern H; Doucette JT
    J Clin Psychiatry; 1993 Apr; 54(4):133-9. PubMed ID: 8098030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of severe and mild tardive dyskinesia: implications for etiology.
    Gardos G; Cole JO; Schniebolk S; Salomon M
    J Clin Psychiatry; 1987 Sep; 48(9):359-62. PubMed ID: 2887550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients.
    Richardson MA; Haugland G; Craig TJ
    Am J Psychiatry; 1991 Oct; 148(10):1322-8. PubMed ID: 1680296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tardive dyskinesia and glucid metabolism.
    Brousse G; Meary A; Mouret J; Blanc O; Hueber T; Lemoine P; Llorca PM; Lachaux B
    Hum Psychopharmacol; 2007 Aug; 22(6):373-80. PubMed ID: 17579925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.